Gene therapy is back in the fast lane. With tough questions around delivery, vector design, redosing, analytics, and scale-up, the 9th Gene Therapy Development Summit 2026 is the deep dive the field needs.
Inside, you’ll find:
- Smarter strategies for extra-hepatic delivery, vector design, and redosing (applicable to both rare and common diseases)
- Manufacturing, regulatory, and commercial insights that help shift gene therapies from one-off programs to scalable solutions
- Unmatched networking opportunities with the leaders and decision-makers shaping the future of gene therapy
Access your free copy of the full eBook now and get aligned with the future of gene therapy development.
About Hanson Wade Group - 9th Gene Therapy Development Summit 2026
Advancing Next-Generation Delivery, Gene Editing, & Assay Development to Optimize the Clinical Impact, Risk–Benefit Profile, & Scalability of Gene Therapies
Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by teams who remain steadfast in their belief that this science can transform lives. Confidence is returning, with significant investments and acquisitions signalling a renewed commitment to overcoming barriers of safety, efficacy, and scalability.
The 9th Gene Therapy Development Summit returns to Boston as the meeting point for this community. Join 100+ leading voices from the likes of Bayer, Astellas Pharmaceuticals, REGENXBIO Ocugen, AskBio, CureDuchenne Ventures, and more to come together to share ideas, restore confidence, and chart a sustainable path forward for gene therapy.
Connect with your peers in pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs for an unrivalled learning and networking opportunity across the end-to-end of gene therapy development.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.